CN115768795A - SIRPα及SIRPβ1抗体及其用途 - Google Patents

SIRPα及SIRPβ1抗体及其用途 Download PDF

Info

Publication number
CN115768795A
CN115768795A CN202180033618.6A CN202180033618A CN115768795A CN 115768795 A CN115768795 A CN 115768795A CN 202180033618 A CN202180033618 A CN 202180033618A CN 115768795 A CN115768795 A CN 115768795A
Authority
CN
China
Prior art keywords
antibody
seq
acid sequence
sirp
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180033618.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·潘尼克
A·D·罗森塔尔
E·L·露丝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elecla Therapeutics
Original Assignee
Elecla Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elecla Therapeutics filed Critical Elecla Therapeutics
Publication of CN115768795A publication Critical patent/CN115768795A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
CN202180033618.6A 2020-05-08 2021-05-10 SIRPα及SIRPβ1抗体及其用途 Pending CN115768795A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022309P 2020-05-08 2020-05-08
US63/022,309 2020-05-08
PCT/US2021/031541 WO2021226576A1 (en) 2020-05-08 2021-05-10 Sirp alpha and sirp beta 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN115768795A true CN115768795A (zh) 2023-03-07

Family

ID=76197640

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180033618.6A Pending CN115768795A (zh) 2020-05-08 2021-05-10 SIRPα及SIRPβ1抗体及其用途
CN202180033623.7A Pending CN115768796A (zh) 2020-05-08 2021-05-10 SIRPα、SIRPβ1及SIRPγ抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180033623.7A Pending CN115768796A (zh) 2020-05-08 2021-05-10 SIRPα、SIRPβ1及SIRPγ抗体及其用途

Country Status (11)

Country Link
US (4) US12503508B2 (https=)
EP (2) EP4146698A1 (https=)
JP (2) JP2023525753A (https=)
KR (2) KR20230017219A (https=)
CN (2) CN115768795A (https=)
AU (2) AU2021267943A1 (https=)
CA (2) CA3177961A1 (https=)
GB (2) GB2613259A (https=)
IL (2) IL298024A (https=)
TW (2) TW202208431A (https=)
WO (2) WO2021226591A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117025547A (zh) * 2023-10-08 2023-11-10 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226591A1 (en) 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
CN118591619A (zh) * 2021-11-24 2024-09-03 雷格细胞股份有限公司 人诱导性调节性t细胞及其制作方法
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之ｓｉｒｐ抗體
WO2025226691A1 (en) 2024-04-22 2025-10-30 Electra Therapeutics, Inc. Sirp alpha and beta antibodies for treatment of epstein–barr virus infections
CN119192379B (zh) * 2024-11-22 2025-01-28 四川省医学科学院·四川省人民医院 一种具有高亲和力的抗SIRPγ单克隆抗体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456749A (zh) * 2014-03-11 2017-02-22 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
CN109689688A (zh) * 2016-08-09 2019-04-26 科马布有限公司 抗icos抗体
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
CN110799536A (zh) * 2017-05-16 2020-02-14 斯索恩生物制药有限公司 抗SIRPα抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
MA47111A (fr) 2016-12-22 2019-10-30 Univ Wake Forest Health Sciences Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
JP7395471B2 (ja) * 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
EP3802602A1 (en) * 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
US20230340112A1 (en) 2020-02-28 2023-10-26 Apexigen, Inc. Anti-sirpa antibodies and methods of use
WO2021226591A1 (en) * 2020-05-08 2021-11-11 Electra Therapeutics, Inc. Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
WO2023086906A2 (en) 2021-11-10 2023-05-19 Electra Therapeutics, Inc. Sirp gamma antibodies and uses thereof
TW202523701A (zh) 2023-10-19 2025-06-16 美商電子療法股份有限公司 用於治療癌症之ｓｉｒｐ抗體
TW202529810A (zh) 2023-10-19 2025-08-01 美商電子療法股份有限公司 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456749A (zh) * 2014-03-11 2017-02-22 小利兰·斯坦福大学托管委员会 抗SIRPα抗体和双特异性巨噬细胞增强型抗体
CN109689688A (zh) * 2016-08-09 2019-04-26 科马布有限公司 抗icos抗体
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
CN110799536A (zh) * 2017-05-16 2020-02-14 斯索恩生物制药有限公司 抗SIRPα抗体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117025547A (zh) * 2023-10-08 2023-11-10 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用
CN117025547B (zh) * 2023-10-08 2023-12-12 迈杰转化医学研究(苏州)有限公司 产生抗b7h3单克隆抗体的杂交瘤细胞株及其应用

Also Published As

Publication number Publication date
US20250197492A1 (en) 2025-06-19
KR20230017793A (ko) 2023-02-06
GB202218421D0 (en) 2023-01-18
JP2023525753A (ja) 2023-06-19
GB2613464A (en) 2023-06-07
AU2021269130A1 (en) 2022-11-24
JP2023525298A (ja) 2023-06-15
GB2613259A (en) 2023-05-31
EP4146699A1 (en) 2023-03-15
US12503508B2 (en) 2025-12-23
GB202218419D0 (en) 2023-01-18
US12187797B2 (en) 2025-01-07
US20230303685A1 (en) 2023-09-28
US20240239888A1 (en) 2024-07-18
KR20230017219A (ko) 2023-02-03
WO2021226591A1 (en) 2021-11-11
EP4146698A1 (en) 2023-03-15
WO2021226576A1 (en) 2021-11-11
IL297982A (en) 2023-01-01
CA3178038A1 (en) 2021-11-11
TW202208430A (zh) 2022-03-01
CA3177961A1 (en) 2021-11-11
IL298024A (en) 2023-01-01
CN115768796A (zh) 2023-03-07
TW202208431A (zh) 2022-03-01
AU2021267943A1 (en) 2022-11-24
US20230174648A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
US20240218076A1 (en) Therapeutic antibodies
CN115768795A (zh) SIRPα及SIRPβ1抗体及其用途
JP2023162190A (ja) 抗ｓｉｒｐａ抗体およびその使用法
EP3928790A1 (en) Cd3 antigen binding fragment and application thereof
BR112021009325A2 (pt) Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
US20240336686A1 (en) Novel multi-specific molecules
AU2015314809A1 (en) Humanized anti-alpha v beta 5 antibodies and uses thereof
TW202521578A (zh) Ｂｔｎ３ａ結合蛋白及其醫藥用途
WO2025230866A1 (en) Anti-alpha5 integrin antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination